Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration. Learn more: bit.ly/4pRWiZy

Hakim Lakhani has been named one of Becker's Healthcare's Patient Safety Experts to Know 2025. His expertise is instrumental in advancing patient safety and improving care delivery. Please join us in congratulating him on this recognition. View the full list here: bit.ly/3WbQHPT

Our experts are at the forefront of research in immunotherapies for blood cancer — from checkpoint inhibitors to CAR T-cell and bispecific antibody trials now shaping treatment. Learn more: bit.ly/3I6dGsz

This weekend, faculty members of Dana-Farber/Boston Children's (@bostonchildrens.bsky.social) Cancer and Blood Disorders Center are presenting at the @theaacr.bsky.social Pediatric Special Conference in Cancer.

We’re honored to be recognized as World’s Best Specialized Hospitals in oncology by @newsweek.com. This recognition highlights our commitment to excellence in oncology care and our dedication to providing world-class treatment for our patients. bit.ly/4ntQ1BM

Through a first-of-its-kind program, @danafarber.bsky.social and Northeastern University are training the next generation of oncology nurses while setting a national standard for academic-clinical collaboration to meet urgent healthcare demands. #DanaFarber #NortheasternUniversity ➡️ bit.ly/48wd0Hp

“The New Face of Cancer” @danafarber.bsky.social’s Kimmie Ng, MD, MPH, joined Trisha Pasricha, MD, MPH, and Shuji Ogino, MD, PhD, at @bostonglobe.com's Future of Medicine Summit, discussing the alarming rise of cancer in adults younger than 55, moderated by @leungboston.bsky.social

New research from Rinath Jeselsohn, MD, and colleagues in @NatureGenet sheds light on why tamoxifen may lead to higher risk of uterine cancer. Learn more: bit.ly/41ZB7dH

In @science.org, @cdumonti.bsky.social of @danafarber.bsky.social discusses his recent publication in the Journal of the National Comprehensive Cancer Network, which introduces simplified methods to detect harmful medications in older cancer patients. Read more: bit.ly/3Keb4cB

More treatments are available for ovarian cancer than ever before. Learn about the latest advances: bit.ly/4676GVw

Research from @nber.org ranks Dana-Farber as No. 1 worldwide for scientific impact, measured by average publications per researcher, their influence, and related patents.

5 things you should know about aggressive prostate cancer — from faster growth to treatment advances. Learn what sets it apart and why awareness matters: bit.ly/4nsvEoa #ProstateCancerAwarenessMonth @danafarber.bsky.social

Dana-Farber/@bostonchildrens.bsky.social is part of a multi-center study that received the Alex’s Lemonade Stand Foundation Crazy 8 Award for their research on early detection and innovative treatments for children predisposed to cancer. Learn more: www.youtube.com/watch?v=ox_Y...

Congratulations Pasi A. Jänne, MD, PhD, on receiving the Adi F. Gazdar IASLC Merit Award at the World Conference on Lung Cancer in Barcelona. This award honors Jänne’s two decades of dedication to advancing lung cancer research and patient care.

Radioligand therapy is more targeted than chemotherapy, killing cancer cells while sparing healthy tissue. Already FDA-approved for cancers like prostate and thyroid, it’s now in clinical trials for additional cancers. Learn more: bit.ly/46chS1T

What’s changing in aggressive prostate cancer care? From PARP inhibitors to radioligand therapies, new treatment approaches are improving outcomes for patients. Learn more: bit.ly/4mC8HP8

Our Office for Faculty Development has received a three-year Institutional Research Grant from the American Cancer Society to support early career investigators. Congratulations to the 2025 recipients: Mu A, PhD; Giacomo Oliveira, PhD; Erin Parry, MD, PhD.

Stem cell transplant has been a standard step in mantle cell lymphoma treatment. New evidence suggests patients in deep remission may not need it, reducing side effects without changing outcomes. Learn more: bit.ly/3I55ZCJ

We’re proud to announce a significant milestone for our Direct Connect program, welcoming its 100th partner. For more information, please visit bit.ly/3HIxl1q.

Join Monique Hartley-Brown, MD, MMSc, and other myeloma community members at the @imfmyeloma.bsky.social Myeloma Community Workshop in Waltham, MA on September 27. The event will include info on the disease, treatments at diagnosis, maintenance therapy, managing side effects, Q&A, & more.

What's on Namrata Singh, PhD's, slide? Singh, pathologist, is using novel microscopy to improve cancer diagnostics and treatment. Learn more: bit.ly/3PSXFqb

Carolyn Lutzko, PhD, has been named the scientific director of the Connell and O’Reilly Families Cell Manipulation Core Facility (CMCF). Please join us in congratulating her on this achievement.

Larisa, Waya, an interfaith chaplain at @danafarber.bsky.social, shares with @wbur.org how she makes deep connections with patients through their tattoos. Read more: bit.ly/4oWkr0t

We are pleased to announce that @ilanaschlam.bsky.social has been named a recipient of the 2025 @harvardmed.bsky.social Faculty Fellowships. Please join us in congratulating her on this honor.

Join members of the lymphoma team for a free webinar on September 10 at 7:30 p.m. to learn about the latest advancements in treatment and ongoing clinical trials for newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma. Register here: bit.ly/46mxKRc

We’re proud to be included in @forbes.com’s Best Employer by State ranking as the #2 employer in Massachusetts. This recognition reflects the dedication of our incredible workforce and the strong culture we’ve built. View the full list here: bit.ly/41XdFxu

In a recent interview with @newsweek.com, Benjamin Ebert, MD, PhD, President and CEO, and Eliezer Van Allen, MD (vanallenlab.bsky.social), explored the potential of AI to transform cancer care and research. Watch the interview here: bit.ly/45ILMup

Join us in September for the Cancer Centers Survivorship Research Forum hosted at Dana-Farber. Connect with experts & peers to advance cancer survivorship care. Register now: bit.ly/3YbrAOQ

Benjamin L. Ebert, MD, PhD, President and CEO, joined David Rubenstein on his new @bloomberg.com TV show, Longevity, for a wide-ranging discussion on cancer.   Watch the full episode here: bit.ly/47E8Cpm

Every August, we come together through these special moments and inspire hope across #RedSoxNation.  Today and tomorrow, we’re back at Fenway Park for the WEEI/NESN Jimmy Fund Radio-Telethon! Donate now: jimmyfund.gives/bluesky

📌 Editor's Note: The MatchMiner #AI tool developed by @danafarber.bsky.social aims to enhance #cancer trial enrollment. Author Kenneth Kehl joins JAMA+ AI EIC Roy Perlis to discuss this and more. ja.ma/45yJ1LV

Did you know bacteria and viruses have been one-upping each other for billions of years? Grad students @joelmjtan.bsky.social and @reneechang.bsky.social explain their discoveries of ancient bacterial "booby traps" and viral defenses and what they mean for cancer research. Learn more: bit.ly/4m2o2Zc

Researchers from the Ghobrial Lab have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma and its precursor conditions. Learn more about the new method, known as SWIFT-seq: bit.ly/4lkMyTY

Please join us in congratulating Alice Shaw, MD, PhD, on being named our next Chair of the Department of Medical Oncology. Learn more: bit.ly/45wiiQ6

In collaboration with @bostonchildrens.bsky.social and Broad Clinical Labs, we’re excited to announce the launch of BrightSeq — a new precision genomics initiative set to advance pediatric cancer diagnostics and research. Learn more: bit.ly/4fL6jTP

New research from a collaborative study between Dana-Farber and @broadinstitute.org shows promise for targeted therapies for pediatric gliomas, the most common form of pediatric brain tumor. The research was published in @natcomms.nature.com. Learn more: bit.ly/45meNf6

In a new @natcancer.nature.com study, @danafarber.bsky.social researchers developed a blood test that could transform the diagnosis and monitoring of #MultipleMyeloma and its precursor conditions with a new method, known as SWIFT-seq. Read more: bit.ly/4lz3iHv

In a study published in @theaacr.bsky.social's Clinical Cancer Research, researcher @jia-luo.bsky.social uncovered the potential for underdiagnosis of NUT carcinoma and identified additional tests required for an accurate diagnosis. Read more: bit.ly/4nW4Ld4

How Your Diet Influences Your Colorectal Cancer Risk: @danafarber.bsky.social’s Dr. Kimmie Ng featured in @nytimes.com discussing why nearly 40% of U.S. colorectal cancer cases could be traced back to poor diet and what can be done to help. ➡️ bit.ly/4m0VX4s

The TODAY Show’s spoke with Billy Starr, the man behind the Pan-Mass Challenge, which has raised $1B+ for cancer research at Dana-Farber. This weekend, thousands of riders, donors, volunteers, and sponsors come together to bring us #CloserByTheMile to change the future of cancer treatment. #PMC2025

Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by @usnews.com, ranked as #3 in the nation and the only one top ranked in New England for 2025-26. Learn more: bit.ly/45e0n0x

Deion Sanders announced he was treated for an aggressive form of bladder cancer. @danafarber.bsky.social’s Dr. Bradley McGregor discussed on ABC News signs and symptoms of the disease, as well as what recovery from treatment could look like. bit.ly/4ogoUei

Vish Viswanath, PhD, professor of Health Communication at Dana-Farber and the Harvard T.H. Chan School of Public Health, has been named a Fellow of the American Association for the Advancement of Science (@aaas.org). Please join us in congratulating him on this honor.

Congratulations to @drmdavids.bsky.social who was awarded the 2025 CLL Society Clinical Scholar Award for his work: Optimizing Glofitamab Combination Therapy in Richter’s Transformation. Read more: bit.ly/4eZLQtP

Filipa Lynce, MD, FASCO, received the Advanced Clinical Research Award in Breast Cancer Research from Conquer Cancer, the @ascocancer.bsky.social Foundation. Lynce's work will focus on deciphering mechanisms of response to novel therapies in HER2 expressing stage III Inflammatory Breast Cancer.

Anuj Patel, MD, recently presented research at @myesmo.bsky.social GI, receiving a Best Poster Award for work on a new ctDNA test designed to detect MRD in patients who undergo curative treatment for locally advanced esophageal cancer. The test demonstrated improved detection of MRD.

Before Benjamin Ebert, MD, PhD, was the CEO, his research redefined blood cancer advancement -- from uncovering RPS14’s role in 5q‑syndrome to revealing how lenalidomide harnesses the proteasome to degrade “undruggable” transcription factors. Learn about his remarkable career: bit.ly/3Iki7zF

Dr. Kimmie Ng of @danafarber.bsky.social spoke with @boston25news.com today about the rising rates of gastrointestinal cancers, including colorectal, gastric, esophageal and pancreatic cancers, among younger adults. ➡️ bit.ly/3TNc2hz

GI cancers are now the fastest-growing types of cancer diagnosed in adults younger than 50 in the U.S. @danafarber.bsky.social’s Kimmie Ng, MD, co-authored the research review and spoke with @nbcnews.com about one of the most comprehensive looks at GI cancer trends. ➡️ bit.ly/3GSbdkC

Early-onset gastrointestinal cancers are among the largest subset of early-onset cancers globally. This JAMA Review summarizes current evidence on early-onset gastrointestinal cancers. https://ja.ma/4lypYYT #OncSky @danafarber.bsky.social